Dosimetric and clinical predictors for radiation-induced esophageal injury.

PURPOSE To evaluate the clinical and three-dimensional dosimetric parameters associated with esophageal injury after radiotherapy (RT) for non-small-cell lung cancer. METHODS AND MATERIALS The records of 254 patients treated for non-small-cell lung cancer between 1992 and 2001 were reviewed. A variety of metrics describing the esophageal dose were extracted. The Radiation Therapy Oncology Group toxicity criteria for grading of esophageal injury were used. The median follow-up time for all patients was 43 months (range, 0.5-120 months). Logistic regression analysis, contingency table analyses, and Fisher's exact tests were used for statistical analysis. RESULTS Acute toxicity occurred in 199 (78%) of 254 patients. For acute toxicity of Grade 2 or worse, twice-daily RT, age, nodal stage of N2 or worse, and most dosimetric parameters were predictive. Late toxicity occurred in 17 (7%) of 238 patients. The median and maximal time to the onset of late toxicity was 5 and 40 months after RT, respectively. Late toxicity occurred in 2%, 3%, 17%, 26%, and 100% of patients with acute Grade 0, 1, 2, 3, and 4 toxicity, respectively. For late toxicity, the severity of acute toxicity was most predictive. CONCLUSION A variety of dosimetric parameters are predictive of acute and late esophageal injury. A strong correlation between the dosimetric parameters prevented a comparison between the predictive abilities of these metrics. The presence of acute injury was the most predictive factor for the development of late injury. Additional studies to define better the predictors of RT-induced esophageal injury are needed.

[1]  C. Hess,et al.  Therapeutic outcome and relation of acute and late side effects in the adjuvant radiotherapy of endometrial carcinoma stage I and II. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Jeffrey D Bradley,et al.  Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[3]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[4]  H. Choy,et al.  Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. , 1999, Seminars in radiation oncology.

[5]  L. Marks,et al.  High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. , 1996, International journal of radiation oncology, biology, physics.

[6]  W. Curran,et al.  Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. , 2000, International journal of radiation oncology, biology, physics.

[7]  F. Mascarenhas,et al.  Acute Secondary Effects in the Esophagus in Patients Undergoing Radiotherapy for Carcinoma of the Lung , 1989, American journal of clinical oncology.

[8]  H. Bartelink,et al.  Radiotherapy combined with low-dose cis-diammine dichloroplatinum (II) (CDDP) in inoperable nonmetastatic non-small cell lung cancer (NSCLC): a randomized three arm phase II study of the EORTC Lung Cancer and Radiotherapy Cooperative Groups. , 1990, International journal of radiation oncology, biology, physics.

[9]  M. Socinski,et al.  High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. , 2002, International journal of radiation oncology, biology, physics.

[10]  P. Maguire,et al.  A new three-dimensional dose distribution reduction scheme for tubular organs. , 2000, Medical physics.

[11]  M. Parmar,et al.  Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial , 1997, The Lancet.

[12]  H. Athanassiou,et al.  Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[13]  P. Maguire,et al.  73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Komaki,et al.  Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. , 1998, International journal of radiation oncology, biology, physics.

[15]  W. Dörr,et al.  Consequential late effects in normal tissues. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[16]  K. Rosenzweig,et al.  Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[17]  H. Beck-Bornholdt,et al.  Radiation-induced impairment of urinary bladder function in mice: fine structure of the acute response and consequences on late effects. , 1999, Radiation research.

[18]  F. Khuri,et al.  Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. , 2002, Seminars in radiation oncology.

[19]  D. Booser,et al.  Esophageal complications from combined chemoradiotherapy (cyclophosphamide + Adriamycin + cisplatin + XRT) in the treatment of non-small cell lung cancer. , 1985, International journal of radiation oncology, biology, physics.

[20]  G Bentel,et al.  Positioning and immobilization of patients undergoing radiation therapy for Hodgkin's disease. , 1991, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[21]  R J Myerson,et al.  Late effects of radiation therapy on the gastrointestinal tract. , 1995, International journal of radiation oncology, biology, physics.

[22]  G. Sibley Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma , 1998, Cancer.

[23]  P. Jacob,et al.  Radiation-induced esophageal injury: a spectrum from esophagitis to cancer. , 1990, The American journal of gastroenterology.

[24]  D. Ettinger,et al.  Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. , 2002, International journal of radiation oncology, biology, physics.

[25]  M. Goitein,et al.  Tolerance of normal tissue to therapeutic irradiation. , 1991, International journal of radiation oncology, biology, physics.

[26]  P. Lorigan,et al.  Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

[27]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[28]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.

[29]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[30]  R. Clough,et al.  Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[31]  P. Maguire,et al.  Clinical and dosimetric predictors of radiation-induced esophageal toxicity. , 1999, International journal of radiation oncology, biology, physics.

[32]  M. Socinski,et al.  Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma , 2001, Cancer.